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Available online 27 December 2016Background: Despite scarce data, invasive mechanical ventilation (MV) is widely recommended over non-
invasive ventilation (NIV) for ventilatory support in cardiogenic shock (CS). We assessed the real-life use of dif-
ferent ventilation strategies in CS and their inﬂuence on outcome focusing on the use of NIV and MV.
Methods: 219 CS patients were categorized by themaximum intensity of ventilatory support they needed during
the ﬁrst 24 h intoMV (n=137; 63%) , NIV (n=26; 12%), and supplementary oxygen (n=56; 26%) groups.We
compared the clinical characteristics and 90-day outcome between the MV and the NIV groups.
Results:Mean age was 67 years, 74%were men. TheMV and NIV groups did not differ in age,medical history, eti-
ology of CS, PaO2/FiO2 ratio, baseline hemodynamics or LVEF. MV patients predominantly presented with hypo-
perfusion, with more severe metabolic acidosis, higher lactate levels and greater need for vasoactive drugs,
whereas NIV patients tended to be more often congestive. 90-day outcome was signiﬁcantly worse in the MV
group (50% vs. 27%), but after propensity score adjustment, mortality was equal in both groups. Confusion,
prior CABG, ACS etiology, higher lactate level, and lower baseline PaO2were independent predictors ofmortality,
whereas ventilation strategy did not have any inﬂuence on outcome.
Conclusions:AlthoughMV is generally recommendedmode of ventilatory support in CS, a fair number of patients
were successfully treated with NIV. Moreover, ventilation strategy was not associated with outcome. Thus, NIV
seems a safe option for properly chosen CS patients.
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.1. Introduction
Cardiogenic shock (CS) is deﬁned as a state of critical end-organ hy-
poperfusion due to reduced cardiac output often resulting in multi-
organ failure. The most frequent cause of CS is acute myocardial infarc-
tion (AMI), but also other cardiac emergencies can lead to shock [1,2].
Despite remarkable advancement in pharmacological and intervention-
al treatment of AMI over the last decades, mortality in CS remains unac-
ceptably high at 40% to 50% [3,4]. Even though patients presenting with
CS are critically ill, their clinical picture can range frommild hypoperfu-
sion to profound treatment-refractory shock. CS patients frequently
have signiﬁcantly elevated pulmonary capillary wedge pressure and
192 M. Hongisto et al. / International Journal of Cardiology 230 (2017) 191–197consequently are prone to pulmonary oedema and respiratory distress.
Most CS patients need some ventilatory support to provide adequate
gas exchange and to relieve thework of breathing. Depending of the se-
verity of ventilatory disturbance, some patients may be managed only
with supplementary oxygen, whereas those suffering from profound
circulatory shock are intubated as a rule.
Themajority of guidelines and reviews recommendmechanical ven-
tilation (MV) in CS [5,6]. However, this recommendation is essentially
based on expert opinion rather than on scientiﬁc data. The role of
noninvasive ventilation (NIV) is well established and studied in acute
cardiogenic pulmonary edema (APE). It has been shown to reduce re-
spiratory distress and the rate of endotracheal intubation [7–9], but de-
spite several studies and meta-analyses, its impact on mortality is still a
matter of debate [10–12]. On one hand, patients presenting with symp-
toms of shock or ST segment elevation myocardial infarction (STEMI)
and those who need urgent coronary revascularization have been ex-
cluded from most of these studies [7,8,11,13]. On the other hand, NIV
has been formally contraindicated in patients with CS because it may
worsen hypotension, and the frequently altered mental status does
not ensure adequate spontaneous ventilation. Little is known about
the use of different ventilatory support strategies in the treatment of
CS. To the best of our knowledge, there are no data comparing the use
of NIV andMV in CS. The aim of our study was to analyze the use of dif-
ferent ventilatory support strategies and their impact on 90-day out-
come in a large cohort of CS patients.
2. Patients and methods
The CardShock study (ClinicalTrials.gov identiﬁer NCT01374867,
registered on 9 June 2011) was conducted at nine European tertiary
care hospitals in eight countries between October 2010 and December
2012. The study population, which comprised 219 prospectively en-
rolled patients with CS, has been described previously [1].
2.1. Inclusion criteria and data collection
Adult patients were enrolled within 6 h from the detection of CS.
In addition to an acute cardiac cause, the inclusion criteria were: sys-
tolic blood pressure had to be b90 mm Hg (after adequate ﬂuid chal-
lenge) for 30 min OR need for vasopressor therapy to maintain
SBP N 90 mm Hg AND signs of hypoperfusion (confusion, cold pe-
riphery, oliguria b0.5 mL/kg/h for the previous 6 h, or blood lactate
N2 mmol/L). Exclusion criteria were shock caused by ongoing hemo-
dynamically signiﬁcant arrhythmias or shock after cardiac or non-
cardiac surgery. The etiology of shock was classiﬁed as acute coro-
nary syndrome (ACS) or non-ACS, and the diagnosis was set by the
local investigators. Baseline characteristics, medical history, clinical
ﬁndings and hemodynamic parameters were recorded at detection
of shock. Biochemical and hemodynamic data as well as treatment
and procedures were registered at baseline and at predeﬁned time
points until 96 h after inclusion. Patients were treated according to
local clinical practice. Written informed consent was obtained from
each patient or a close person or a relative if the patient was unable
to give the consent on admission.
Assessing the need for ventilatory assistance and the choice of ventila-
torymode (room air, supplementary oxygen, NIV orMV)were at the dis-
cretion of the physician in charge and based on common indications and
contraindications for NIV and MV treatment. Arterial blood gas samples
were analyzed locally at baseline and at pre-speciﬁed time points thereaf-
ter. PaO2/FiO2 ratiowas calculated using themeasured PaO2 and reported
FiO2. The degree of hypoxemia and respiratory failure was classiﬁed ac-
cording to Berlin deﬁnition ARDS (acute respiratory distress syndrome)
criteria: mild (200 mm Hg b PaO2/FiO2 ≤ 300 mm Hg), moderate
(100 mm Hg b PaO2/FiO2 ≤ 200 mm Hg), and severe (PaO2/FiO2 ≤
100 mm Hg) [14]. Estimated glomerular ﬁltration rate (eGFR) wascalculated from creatinine values using the CKD-EPI (Chronic Kidney Dis-
ease Epidemiology Collaboration) equation [15].
We categorized the patients by the maximum intensity of ventilato-
ry support during the ﬁrst 24 h in three groups: invasive MV group, NIV
group (including both continuous positive airway pressure and bilevel
positive airway pressure) and supplementary oxygen group (including
patients treatedwith supplementary oxygen only bymask or nasal can-
nulas). We analyzed their clinical characteristics, treatment and out-
come. The supplementary oxygen therapy group was not included in
further comparisons. Patients who died during the ﬁrst 24 h were in-
cluded if they received NIV or MV treatment. The primary endpoint
was all-cause 90-day mortality; three patients were lost to follow up.
NIV failure was deﬁned as requirement for endotracheal intubation
after NIV as a ﬁrst line ventilatory support mode. Vital status during
follow-up was determined through direct contact with the patient or
next of kin, or through population and hospital registers. The study
was approved by local ethics committees (detailed later after discus-
sion) and conducted in accordance with the Declaration of Helsinki.
2.2. CardShock risk Score
The CardShock risk Score is a risk prediction model for in-hospital
mortality in CS that has been created by using the variables which inde-
pendently associated with all-cause death in the CardShock study [1].
The Score consists of seven parameters [age N75 years, eGFR, blood lac-
tate, confusion on admission, left ventricular ejection fraction (LVEF)
b40%, previous myocardial infarction (MI) or coronary artery bypass
grafting (CABG), andACS etiology] giving amaximumof ninepoints. Pa-
tients can be classiﬁed according to the risk Score into low, intermedi-
ate, and high risk groups regarding in-hospital mortality.
2.3. Statistical analysis
Results are presented as numbers (n) and percentages (%) for cate-
gorical variables, and for continuous variables asmean and standard de-
viation (SD) or median and interquartile range (IQR), as appropriate.
Chi-squared test and Fisher's exact test were used to compare categor-
ical variables, and Student's t-test, Wilcoxon signed rank test and
Mann–Whitney U test were used for continuous variables, as appropri-
ate. Multivariable logistic regression analysis was used to determine in-
dependent risk factors for 90-day mortality. In order to avoid model
over-ﬁtting, independent predictors of 90-daymortalitywere identiﬁed
from selected variables known to be clinically related to outcome. The
modelwas also adjusted for CardShockRisk Score variables, age, gender,
and participating center. Results from the regression analyses are pre-
sented as odd ratios (OR) with 95% conﬁdence intervals (CI).
Propensity score adjustment was used to diminish bias and increase
precision in analyses assessing the relationship between ventilatory
treatment and mortality [16]. Propensity score was created using logis-
tic regression modeling the likelihood of a patient receiving either NIV
or MV. Variables were chosen based on clinical relevance and on poten-
tial or observed associationwith outcome [1]. The ﬁnal propensity score
was estimated with the following variables: age, gender, medical histo-
ry (myocardial infarction, coronary artery bypass graft surgery, diabetes
mellitus, hypertension), acute coronary syndrome etiology, and initial
presentation (confusion, blood lactate, systolic blood pressure, non-
sinus rhythm, left ventricular ejection fraction, and estimated glomeru-
lar ﬁltration rate (CKD-EPI)). The score estimate was transformed into
logit scale [17]. The Kaplan-Meier method was used for unadjusted
and the Cox regression for adjusted survival analyses; the assumption
of proportional hazardswas checkedwith parallelism of log-log survival
curves. The variables included in the propensity score adjustment anal-
ysis are stated below the Fig. 1. A two-sided p-value b0.05was regarded
as statistically signiﬁcant. All statistical analyses were performed with
SPSS 22.0 statistical software (IBM Corp, Armonk, NY, USA).
Fig. 1. A) Unadjusted (Kaplan Meier) and B) propensity score adjusted (Cox regression)
survival curves for the use of MV (solid line) and NIV (dashed line). MV, invasive
mechanical ventilation group; NIV, noninvasive ventilation group. Adjusted for logit of
the propensity score, which was estimated with the following variables: age, gender,
medical history (myocardial infarction, coronary artery bypass graft surgery, diabetes
mellitus, hypertension), acute coronary syndrome, and initial presentation (confusion,
blood lactate, systolic blood pressure, non-sinus rhythm, left ventricular ejection
fraction, and estimated glomerular ﬁltration rate (CKD-EPI)).
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3.1. Study population
A total of 219 patientswere included in the study. Themain character-
istics of the study population are summarized in Table 1. Brieﬂy, themean
age was 67 (SD 12) years, and 26% were women. ACS was the most fre-
quent cause of CS (81%, n = 177). At baseline, the blood pressure was
on average 78/40 mm Hg and heart rate 90 beats per minute. Median
length of hospital stay was 12 (IQR 7–25) days, and 90-day mortality
was 41%.
3.2. Mechanical ventilation (MV) and noninvasive ventilation (NIV)
During the ﬁrst 24 h, 30 patients were initially treated with NIV.
Eight of these patients had to be intubated (NIV failure). Half of the fail-
ures occurred during the ﬁrst 24 h, and the rest later during the subse-
quent 24 to 96 h. Those four patients initially treated with NIV andshifted to MV during the ﬁrst 24 h have been included in the MV
group. In comparing ventilation modes, 63% (n = 137) of the patients
were classiﬁed as treated with MV, and 12% (n=26) with NIV. Clinical
characteristics and baseline information of the patients who required
oxygen only by mask or nasal cannula (n = 56; 26%) are presented in
Tables 1-3 as a “Supplementary oxygen group”. Because this group dif-
fers from the NIV and the MV groups, especially with regard to the se-
verity of the respiratory failure (Table 3), it was not included in
further comparisons.
Clinical characteristics between theMV and the NIV groups are com-
pared in Table 1. There were no signiﬁcant differences between the
groups in age, gender, or medical history. In both groups, over 50% of
the patients were smokers or ex-smokers, but few had a diagnosed
chronic lung disease. The proportion of patients with ACS etiology of
CS was similar in both groups. Clinical presentation and biochemistry
at baseline are shown in Tables 1 and 2. The NIV group had slightly
higher systolic blood pressure, but the groups did not differ otherwise
in hemodynamic parameters or LVEF at baseline. Patients in the MV
groupweremore often confused (83% vs. 31%, p b 0.001) and had higher
lactate levels (3.7 vs. 1.7 mmol/L, p b 0.001). MV patients also received
vasoactive medication more frequently (norepinephrine 88% vs. 69%,
p = 0.03; dobutamine 61% vs. 27%, p = 0.001), with the exception of
levosimendan (22% vs. 58%, p b 0.001) that was administered more
often to patients in the NIV group. Noninvasively ventilated patients
had higher hs-TnT (3631 vs. 1597 ng/L; p = 0.06) and NT-proBNP
(7375 vs. 2367 ng/L; p = 0.04) levels (Table 2). Revascularization
rates did not differ between the groups. Forty percent of MV patients
had been resuscitated before inclusion into the study.
3.3. Ventilatory parameters and mortality
Ventilatory parameters at baseline and at 24 h are presented in
Table 3. Patients treated with MV suffered from metabolic acidosis
more often and were treated with higher oxygen fraction at baseline
compared with NIV group. The MV group had also slightly higher
PaO2 and PaCO2 levels. In terms of PaO2/FiO2 ratio, the degree of respi-
ratory failure was moderate in both groups at baseline but improved
with both respiratory modalities during the ﬁrst 24 h. The level of pos-
itive end-expiratory pressure (PEEP) ranged in the NIV group from 5 to
12 cmH2O with a median level of 8 cmH2O (IQR 7.5–10) and in the MV
group from 4 to 14 cmH2O with a median level of 6 cmH2O (IQR 5–8),
respectively. The duration of the ventilation was signiﬁcantly longer in
the MV group.
Outcome and length of stay for each group are shown in Table 2. In-
hospital mortality was 45% in the MV group and 19% in the NIV group
(p= 0.01), and 90-day mortality was 49% and 27% (p= 0.03), respec-
tively. However, after adjustment for severity of disease using variables
of the CardShock risk Score, ventilation strategy had no inﬂuence on the
90-day outcome. The results remained unchanged when ventilation
strategy was analyzed up to 96 h. Interestingly, higher PaO2 at baseline
was independently associated with better outcome. Whether the pa-
tient was resuscitated or not did not have an effect on outcome when
tested in multivariable analysis. Adjusted ORs for variables associated
with 90-day mortality are shown in Table 4. The propensity score ad-
justment analysis conﬁrmed that ventilation strategy did not inﬂuence
the mortality rate (Fig. 1). We performed an additional propensity
score analysis excluding the resuscitated patients but this did not affect
the results (Supplementary material online, Fig. S1).
4. Discussion
To our knowledge, this prospectivemultinational study is the ﬁrst to
provide information about contemporary use of different ventilation
modalities in CS. First, we found that while the majority of patients
were intubated and mechanically ventilated, one fourth did not need
ventilatory support at all. Second, NIV treatment was used successfully
Table 1
Patient characteristics and etiology of cardiogenic shock.
All
(n = 219)
MV
(n = 137)
NIV
(n = 26)
p-Value⁎ Supplementary oxygen
(n = 56)
Age, years 67 (12) 66 (11) 66 (12) 0.8 68 (13)
Women, n (%) 57 (26) 31 (23) 8 (31) 0.4 18 (32)
BMI 26.9 (4.2) 27.4 (3.9) 26.4 (4.3) 0.3 25.8 (4.5)
Medical history, n (%)
Coronary artery disease 76 (35) 51 (37) 10 (39) 0.9 15 (27)
Previous MI 54 (25) 35 (26) 8 (31) 0.6 11 (20)
Prior CABG 16 (7) 11 (8) 4 (15) 0.3 1 (2)
Heart failure 36 (16) 25 (18) 3 (12) 0.6 8 (14)
Hypertension 132 (60) 85 (62) 17 (65) 0.7 30 (54)
Diabetes 62 (28) 44 (32) 6 (23) 0.4 11 (20)
Asthma or COPD 25 (11) 18 (13) 2 (8) 0.7 5 (9)
Smoker or ex-smoker 135 (62) 95 (69) 14 (54) 0.2 26 (47)
Etiology of cardiogenic shock, n (%)
ACS 177 (81) 111 (81) 20 (77) 0.6 46 (82)
non-ACS 42 (19) 26 (19) 6 (23) 0.6 10 (18)
STEMI 148 (68) 87 (64) 18 (69) 0.6 43 (77)
Resuscitated, n (%) 62 (28) 55 (40) 0 7 (13)
Data are presented as numbers and percentages (%), mean (SD), and median (IQR).
⁎ p-Values are for the difference between MV and NIV group. MV, invasive mechanical ventilation group; NIV noninvasive ventilation group; BMI, body mass index; SD, standard de-
viation; MI, myocardial infarction; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; ACS, acute coronary syndrome; STEMI, ST-elevation myocardial
infarction.
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sociated with increased mortality even after adjustment for severity of
disease. Fourth, higher PaO2 on admission was associated with better
prognosis.
There are scarce data available on the use of different respiratory
modalities in CS. In the AHEAD (Acute Heart Failure Database) registry
study, 8% of the subgroup of CS (n = 600) were treated with NIV and
56% with MV [18]. Only 11.6% of these CS patients underwent coronary
angiography, suggesting a different patient population compared to the
patients in our study, in whom coronary angiographywas performed in
83%. In another British study assessing the outcome of CS patients un-
dergoing percutaneous coronary intervention (PCI), only 28.4% were
treated with MV [19]. This contrasts with the IABP-SHOCK II trial, inTable 2
Physiologic parameters at baseline, mortality, and length of ICU/CCU and hospital stay.
All (n = 219) MV (n = 137)
Clinical ﬁndings
Systolic blood pressure, mmHg 78 (14) 78 (15)
Heart rate, beats per minute 90 (28) 91 (29)
LVEF, % 33 (14) 32 (14)
Confusion, n (%) 148 (68) 113 (83)
Biochemistry
Blood hemoglobin, g/L 128 (22) 130 (23)
Arterial blood lactate, mmol/L 2.8 (1.7–5.8) 3.7 (2.2–7.0)
hsTnT, ng/L 2190 (388–5418) 1597 (337–4178)
NT-proBNP, pg/mL 2710 (585–9434) 2367 (559–8563)
Creatinine, mmol/L 104 (78–140) 110 (87–144)
eGFR, mL/min/1.73 m2 61 (41–87) 64 (30)
CRP, g/L 16 (4–54) 15 (4–49)
Management, n (%)
Coronary angiography 182 (83) 114 (83)
PCI 149 (68) 90 (66)
CABG 9 (4) 5 (4)
IABP 122 (56) 85 (62)
Mortality, n (%)
In-hospital mortality 80 (37) 62 (45)
90-day mortality 89 (41) 67 (49)
ICU/CCU length of stay, days 5 (2−10) 6 (2−11)
In-hospital length of stay, days 12 (7–25) 17 (10–27)
Data are presented as numbers and percentages (%), mean (SD), and median (IQR).
⁎ p-Values are for the difference between MV and NIV groups. MV, invasive mechanical ven
hsTnT, highly sensitive troponin; eGFR, estimated glomerular ﬁltration rate; PCI, percutaneou
pump; ICU, intensive care unit; CCU, cardiac care unit.which 80% of patients were mechanically ventilated [20]. A recent
French registry study reported that in intensive care units 75% of CS pa-
tientswere treatedwithMV and 7%withNIV [21]. Contrary to this study
we recruited patients from emergency departments, cardiac and inten-
sive care units, as well as catheter laboratories, and thus included prob-
ably also milder forms of shock which can account for the smaller need
for MV in our study. In addition, the shock was caused by AMI in only
12% of the patients differing clearly from our population. Our multina-
tional, multicenter study shows that the majority of CS patients indeed
are treatedwith ventilatory support, mostly with MV, but also with NIV
with success.
The overall mortality of 41% observed in our study is comparable
with other recent studies on CS [4,19,22,23]. The 90-day mortality wasNIV (n = 26) p-Value⁎ Supplementary oxygen (n = 56)
83 (10) 0.03 75 (11)
87 (23) 0.2 89 (29)
33 (12) 0.7 36 (17)
8 (31) b0.001 26 (46)
125 (22) 0.3 124 (24)
1.7 (1.4–2.8) b0.001 2.3 (1.6–3.5)
3631 (1289–10,170) 0.06 2427 (418–7459)
7375 (2053–17,372) 0.04 1860 (511–8976)
100 (69–119) 0.1 107 (84–140)
67 (28) 0.6 59 (28)
37 (6–79) 0.2 15 (4–48)
23 (89) 0.8 45 (80)
19 (73) 0.5 40 (71)
3 (12) 0.1 1 (2)
16 (62) 1.0 21 (38)
5 (19) 0.01 13 (23)
7 (27) 0.03 15 (27)
4 (2–8) 0.2 3 (1–7)
12 (7–27) 0.2 8 (4–18)
tilation group; NIV noninvasive ventilation group; LVEF; left ventricular ejection fraction;
s coronary intervention; CABG, coronary artery bypass grafting; IABP, intra-aortic balloon
Table 3
Arterial blood gas values, ventilatory parameters at baseline and at 24 h, and duration of ventilation.
MV (n = 137) NIV (n = 26) p-Value⁎ Supplementary oxygen (n = 56)
At baseline
pH 7.27 (7.17–7.34) 7.39 (7.32–7.43) b0.001 7.38 (7.30–7.44)
PaO2, kPa 12.9 (10.4–18.6) 11.2 (9.9–15.0) 0.2 13.40 (9.2–16.8)
PaCO2, kPa 5.5 (4.9–6.4) 4.5 (4.2–5.9) 0.01 4.9 (3.9–5.6)
HCO3, mmol/L 19.6 (15.9–21.5) 22.0 (20.5–24) 0.001 21.9 (16.7–23.4)
FiO2, % 76 (22) 60 (19) 0.001 32 (26)
P/F ratio, mm Hg 141 (97–211) 167 (107–215) 0.3 311 (200–358)
200–300 mm Hg, n (%) 35 (26) 7 (27) 0.9 7 (13)
100–200 mm Hg, n (%) 54 (40) 14 (54) 0.2 7 (13)
b100 mm Hg, n (%) 40 (29) 4 (15) 0.1 0
At 24 h
pH 7.40 (7.35–7.43) 7.42 (7.38–7.46) 0.05 7.43 (7.40–7.46)
PaO2, kPa 12.1 (10.5–14.0) 11.8 (10.4–13.6) 0.5 11.1 (10.0–13.1)
PaCO2, kPa 5.30 (4.70–5.70) 4.50 (4.20–4.90) b 0.001 4.8 (4.3–5.5)
HCO3, mmol/L 24 (21.3–26.3) 23 (21–25) 0.2 24 (21–25)
FiO2, % 52 (18) 53 (23) 0.8 27 (17)
P/F ratio, mm Hg 192 (138–265) 1,2 191 (136–284) 2 1.0 302 (239–396)
200–300 mm Hg, n (%) 33 (24) 6 (23) 0.9 7 (13)
100–200 mm Hg, n (%) 46 (34) 8 (31) 0.7 3 (5)
b100 mm Hg, n (%) 13 (10) 3 (12) 0.7 0
Duration of ventilation, h 94 (30–184) 41 (28–71) 0.007
Data are presented as numbers and percentages (%), mean (SD), and median (IQR).
MV, invasivemechanical ventilation group;NIV noninvasive ventilation group; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial pressure of carbon dioxide in arterial blood,
FiO2, fraction of inspired oxygen; P/F ratio, PaO2/FiO2 ratio.
⁎ p-Values are for the difference between MV and NIV groups. 1) the improvement during the 24 h was signiﬁcant in the MV group, 2) but not between the groups.
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multiple covariates and baseline characteristics by using propensity
score method, the ventilation strategy did not have an effect on out-
come. The outcome of patients treated with NIV was better in our
study than in the AHEAD study, which showed a 62.7% in-hospital mor-
tality in the NIV group, and an even worse prognosis for those treated
with MV, whose in-hospital mortality was 71.8% [18].
Compared to patients treated with NIV, those requiring MV were
more often confused, had metabolic acidosis, higher lactate levels, and
greater need for vasoactive drugs indicating a more severe tissue hypo-
perfusion and shock, whereas the NIV group had higher NT-proBNP
levels, possibly indicating a greater distension of the ventricles and ele-
vatedﬁlling pressure. In terms of PaO2/FiO2 ratio, the degree of acute re-
spiratory failure (ARF) at baseline was moderate in both groups and
improved equally during the ﬁrst 24 hwith both respiratorymodalities.
Since the degree of respiratory failure improved equally with both ven-
tilation strategies, probably the more severe shock and hypoperfusion
accounted for the longer duration of the ventilation in the MV group.
In general, there are no speciﬁc recommendations concerning indi-
cations for NIV or intubtion and MV in CS except in isolated right ven-
tricular failure, where caution is advised due to possible undesirable
effect of positive end-expiratory pressure on right ventricular afterload
and function. Our study suggests that CS patients with congestion andTable 4
Multivariable regression analysis for 90-day mortality.⁎)
Variable Adjusted OR (95% CI) p-Value
Age N 75 years 1.62 (0.45–5.86) 0.47
Confusion 5.22 (1.30–21.00) 0.02
Prior CABG 25.57 (1.57–417.76) 0.02
ACS etiology 4.69 (1.13–19.46) 0.03
Ventilation mode⁎⁎) 0.85 (0.15–4.80) 0.85
eGFR (per 10 mL/min/1.73 m2 increase) 0.96 (0.78–1.19) 0.72
LVEF (per 10% increase) 0.79 (0.50–1.25) 0.31
Lactate (per mmol/L increase) 1.47 (1.17–1.84) 0.001
PaO2 (per kPa increase at baseline) 0.93 (0.88–0.99) 0.02
OR, odds ratio; CI, conﬁdence interval; CABG, coronary artery bypass grafting; ACS, acute
coronary syndrome; eGFR, estimated glomerular ﬁltration rate; LVEF, left ventricular ejec-
tion fraction.
⁎ The mode included also variable accounting for participating center and sex.
⁎⁎ The reference factor is NIV.mild-to-moderate respiratory failure, able to co-operate, and without
signs of severe hypoperfusion can be safely treated with NIV. Success
rate of NIV during the ﬁrst 24 h was 87%, which is higher than in previ-
ous studies assessing the use of NIV in ARF in intensive care units
[24–26]. However, patients who do not improve with NIV treatment
should be promptly intubated, and NIV trial should not delay intubation
and mechanical ventilation when needed. It is also crucial to start the
NIV treatment in a very early phase of respiratory failure, preferably al-
ready in the out-of hospital setting [27,28].
There are several advantages in NIV compared with MV. NIV allows
patients to communicate, eat, move at least to some extent, and breathe
spontaneously. By avoiding endotracheal intubation and invasive MV,
the risks of nosocomial infections, ventilator-associated pneumonia
and injuries related to the intubation procedure itself are diminished
[29,30]. By using NIV instead of MV, the administration of complete se-
dation with loss of vasomotor tone can be avoided. This might be espe-
cially beneﬁcial in patients presenting with symptoms of shock, in
whom the sedatives may increase hypotension.
Higher PaO2 at baseline predicted improved outcome independent-
ly. This is striking, since studies assessing the impact of hyperoxemia on
outcome during critical illness have demonstrated excess oxygen to be
harmful [31]. Arterial hyperoxia has been shown to induce vasocon-
striction and reduce cardiac output, which may impair blood ﬂow to
the organs at risk [32]. Indeed, these effects could be considered espe-
cially harmful in CS. However, there are several important differences
between these studies assessing the role of hyperoxemia on outcome
and the present one. First, the previous studies have focused only on
certain patient populations, e.g. patients with cardiac arrest, traumatic
brain injury or stroke, and thus probably cannot be generalized into
general intensive care unit population. Second, the level of hyperoxemia
among the studies has varied and has in some of the trials been 40 kPa
(300 mm Hg) or even more [33], which is clearly higher than the
average PaO2 level in our study. Furthermore, some of the studies ex-
cluded patients presenting with hypoxemia [(PaO2/FiO2 ratio b27 kPa
(200mmHg) or PaO2 b8 kPa (60mmHg)] [33],whereasmost of thepa-
tients in our study had PaO2/FiO2 ratio below 27 kPa (200 mm Hg).
However, there are preliminary data indicating that by inducing periph-
eral vasoconstriction, hyperoxemia may prevent shock-induced hypo-
tension and decrease the need for use of vasopressor and thus help to
stabilize hemodynamics in vasodilatory shock [34]. In the present
196 M. Hongisto et al. / International Journal of Cardiology 230 (2017) 191–197study, the severity of shock and underlying cardiovascular status were
clearly the main determinants of prognosis, whereas the ventilation
strategy did not have an effect on outcome.
Guidelines do not recommend using NIV in patients presentingwith
ACS or APE and suffering from shock or low blood pressure, or requiring
urgent coronary revascularization [5,6,35]. In many studies regarding
the use of NIV in APE or ARF, the presence of low blood pressure, need
for vasoactive medication or shock have been considered as exclusion
criteria or as criteria for intubation [7,8,13,36,37]. In our experience,
NIV is feasible during angiography and PCI, and the study results suggest
that NIV can be safely used in patients presenting with severe hemody-
namic impairment treated with vasoactive drugs. Our ﬁndings are also
supported by a recently published propensity-based analysis, which
demonstrated that presence or absence of shock did not have an effect
on mortality in APE patients treated with CPAP [38].4.1. Limitations
There are some limitations to be acknowledged. First, although the
CardShock study was prospective and included a reasonable number
of patients, the limited number of patients treated with NIV decreased
the statistical power in between-group comparisons. Second, the choice
of ventilation strategy was at the discretion of the physician in charge.
However, the study reﬂects real life practice in European tertiary care
hospitals. Third, the study lacks randomization and confounding by in-
dication is a possible bias. We used regression and propensity score
methods to minimize this bias, and though differences in some unmea-
sured confounding variables cannot be excluded, the results regarding
the safety of NIV use were consistent. Finally, the number of patients
in theNIV group fromwhom a complete serial blood gas datawas avail-
able was limited, and caution in the interpretation of the results is
advocated.5. Conclusions
In this observationalmulticenter study, we observed that NIV can be
safely used in properly selected patients in cardiogenic shock. Ventila-
tion strategy did not affect outcome. In conclusion, it seems that in high-
ly skilled centers, NIV can be used in the treatment of respiratory failure
in CS. However, appropriate patient selection and closemonitoring dur-
ing the treatment are crucial, and NIV trial should not delay intubation
and mechanical ventilation when indicated.
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